Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248287 · ClinicalTrials.gov registry record · Phase 2
PhII ICb With/Without Erbitux in MBC Pts
A Phase 2 study of Metastatic Breast Cancer, sponsored by US Oncology Research.
- Active
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
- 20
- Study locations
NCT00248287: Active Phase 2 study of Metastatic Breast Cancer, sponsored by US Oncology Research.
NCT00248287 is a Phase 2 study of Metastatic Breast Cancer that is active but no longer recruiting, run by US Oncology Research. The registered enrollment target is 154 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00248287, a Phase 2 study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by US Oncology Research.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.
Primary Outcome
To determine the objective response rates (CR + PR). Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
Conditions Studied
Interventions
- DRUG Irinotecan + Carboplatin
- DRUG irinotecan + Carboplatin + erbitux
Study Locations (20)
Florida
- Melbourne Internal Medicine Associates - Melbourne
- Florida Cancer Institute - New Port Richey
- Ocala Oncology Center - Ocala
- Cancer Centers of Florida, P.A. - Ocoee
Arizona
- Hematology Oncology Asscociates - Phoenix
- Northern AZ Hematology & Oncology Assoc - Sedona
Missouri
- Missouri Cancer Associates - Columbia
- Arch Medical Services, Inc - St Louis
New Jersey
- Hematology-Oncology Associates of NNJ, P.A. - Morristown
- Summit Medical Group - Summit
Alabama
- Birmingham Hematology and Oncology - Birmingham
Colorado
- Rocky Mountain Cancer Center-Rose - Denver
Connecticut
- Northwestern Connecticut Oncology Hematology Associates - Torrington
Illinois
- Hematology Oncology Associates of IL - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2005-07-28 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT00248287 still lists
NCT00248287 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Irinotecan + Carboplatin is the first listed.
NCT00248287 names 20 study sites across 14 states, led by Florida, Arizona, Missouri.
Frequently Asked Questions
What is clinical trial NCT00248287 about?
NCT00248287 is a clinical study titled "PhII ICb With/Without Erbitux in MBC Pts". The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.
What is the current status of trial NCT00248287?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2005-07-28. Estimated completion is 2026-12.
What conditions does trial NCT00248287 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT00248287?
The interventions under investigation include: Irinotecan + Carboplatin (DRUG), irinotecan + Carboplatin + erbitux (DRUG).
Who is sponsoring clinical trial NCT00248287?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00248287 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00248287's enrollment target sits among peer trials
154 42nd of 139 higher than 98 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI